Profusa, Inc. (NASDAQ:PFSA – Free Report) shares are going to reverse split on Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 16th.
Profusa Stock Down 1.5%
Shares of NASDAQ PFSA traded down $0.01 during trading on Thursday, hitting $0.95. 197,899 shares of the company were exchanged, compared to its average volume of 624,052. The company has a fifty day moving average price of $2.85 and a 200-day moving average price of $25.06. Profusa has a 12-month low of $0.81 and a 12-month high of $1,297.50.
Analyst Ratings Changes
A number of equities analysts have commented on PFSA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Profusa Company Profile
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
See Also
- Five stocks we like better than Profusa
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
